Published in Endocr Rev on September 04, 2012
Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation. Philos Trans R Soc Lond B Biol Sci (2014) 0.98
Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity. J Biol Chem (2013) 0.93
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer. Cancer Manag Res (2014) 0.92
Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer. Front Genet (2014) 0.87
Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit (2015) 0.87
IQGAP1 binds to estrogen receptor-α and modulates its function. J Biol Chem (2014) 0.86
Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry. Steroids (2015) 0.85
Xenoestrogens alter estrogen receptor (ER) α intracellular levels. PLoS One (2014) 0.84
Retracted Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci (2014) 0.84
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients. Oncotarget (2015) 0.81
Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biol Ther (2016) 0.80
In search of novel drug target sites on estrogen receptors using RNA aptamers. Nucleic Acid Ther (2014) 0.80
Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front Cell Dev Biol (2014) 0.80
Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan. Virchows Arch (2014) 0.79
A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy. ChemMedChem (2013) 0.78
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. J Transl Med (2014) 0.77
Genetically engineered ERα-positive breast cancer mouse models. Endocr Relat Cancer (2014) 0.77
MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression. Int J Biol Sci (2015) 0.77
A systematic in silico mining of the mechanistic implications and therapeutic potentials of estrogen receptor (ER)-α in breast cancer. PLoS One (2014) 0.76
Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex. Int J Nanomedicine (2015) 0.75
A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. Mol Cancer Res (2016) 0.75
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res (2015) 0.75
MicroRNAs in the development and neoplasia of the mammary gland. F1000Res (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem (2004) 14.93
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell (2000) 11.10
A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 9.80
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 8.01
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev (1999) 7.06
Cells of origin in cancer. Nature (2011) 6.85
Functional domains of the human estrogen receptor. Cell (1987) 6.52
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol (2000) 5.53
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell (1999) 5.23
An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell (1986) 5.22
Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology (2004) 5.20
Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development (2000) 5.03
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol (2005) 4.71
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell (2003) 4.52
Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst (2006) 4.47
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet (2010) 4.06
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem (2001) 3.86
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol (2006) 3.71
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature (1999) 3.42
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol (2007) 3.39
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A (2006) 3.32
Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A (1984) 3.25
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell (2000) 3.23
A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol (2005) 3.19
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst (2007) 3.11
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (2008) 3.09
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res (2007) 2.95
Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol (2001) 2.93
Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol (2006) 2.90
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res (2008) 2.80
A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev (2006) 2.76
G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res (2007) 2.71
High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med (2008) 2.67
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
Nuclear receptor coregulators and human disease. Endocr Rev (2007) 2.65
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A (2004) 2.64
Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol (2003) 2.57
The expanding cosmos of nuclear receptor coactivators. Cell (2006) 2.57
The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer (2011) 2.56
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Retracted Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell (2009) 2.48
Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A (2010) 2.46
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res (2009) 2.43
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. J Biol Chem (2008) 2.34
Think globally, act locally: the making of a mouse mammary gland. Genes Dev (1998) 2.34
Genomic targets of nuclear estrogen receptors. Mol Endocrinol (2004) 2.34
Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature (2002) 2.32
Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer (2007) 2.30
The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A (2009) 2.29
A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A (2006) 2.29
Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics (1997) 2.28
Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res (2009) 2.27
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol (2005) 2.20
Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A (1999) 2.19
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem (2001) 2.16
Inducible regulatory elements in the human cyclin D1 promoter. Oncogene (1994) 2.16
MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell (2006) 2.15
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol (2002) 2.45
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol (2010) 2.03
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Suicide an emerging public health problem: evidence from rural Haryana, India. Indian J Public Health (2013) 2.03
Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr (2014) 2.02
Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem (2006) 2.00
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Taxonomic studies on genus Tetramorium Mayr (Hymenoptera, Formicidae) with report of two new species and three new records including a tramp species from India with a revised key. Zookeys (2012) 1.92
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Retracted Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem (2010) 1.71
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2013) 1.63
Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2014) 1.63
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci (2006) 1.63
Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med (2008) 1.61
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol (2010) 1.60
Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol (2004) 1.59
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56
Thyroid scintigraphy in detecting dual ectopic thyroid: a review. Eur J Nucl Med Mol Imaging (2008) 1.54
Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer (2010) 1.54
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
Community Perception and Client Satisfaction about the Primary Health Care Services in an Urban Resettlement Colony of New Delhi. Indian J Community Med (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Dyke-Davidoff-Masson syndrome. Indian Pediatr (2008) 1.51
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Hallmarks of mechanochemistry: from nanoparticles to technology. Chem Soc Rev (2013) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med (2011) 1.47
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2005) 1.44
Dual ectopic thyroid: case series and review of the literature. Clin Nucl Med (2007) 1.44
18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun (2011) 1.44
Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med (2010) 1.43
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett (2003) 1.43
MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal (2007) 1.43
Persistent renin-angiotensin system activation after anti-reflux surgery and its management. J Pediatr Urol (2011) 1.43
Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosimetry (2005) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
Long term outcome of management of antenatally diagnosed pelvi-ureteric junction obstruction. Indian J Pediatr (2011) 1.41
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol (2002) 1.39
Direct radionuclide cystography by supra-pubic puncture: comparison with conventional voiding cystourethrography. Nucl Med Commun (2004) 1.39
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
National leadership: driving forward the updated Global Strategy for Women's, Children's and Adolescents' Health. BMJ (2015) 1.38
Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol (2006) 1.36
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer (2006) 1.34
Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem (2005) 1.34
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res (2007) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep (2004) 1.34
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem (2004) 1.33
Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res (2007) 1.31
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem (2006) 1.31
Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. Bioorg Med Chem (2005) 1.30
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature (2010) 1.29
Crossed fused renal ectopia: Challenges in diagnosis and management. J Indian Assoc Pediatr Surg (2013) 1.29
E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A (2009) 1.28
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett (2003) 1.27
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther (2009) 1.25
Signaling-dependent and coordinated regulation of transcription, splicing, and translation resides in a single coregulator, PCBP1. Proc Natl Acad Sci U S A (2007) 1.25
Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res (2005) 1.25